INFECCIÓN CRÓNICA ACTIVA POR VIRUS EPSTEIN BARR

Ramiro Sa Silva; Eira García; Emma González

Enviado octubre 30, 2024

Publicado 2026-04-06

Artículos de Investigación

Vol. 22 Núm. 1 (2009): Revista Médico Científica

INFECCIÓN CRÓNICA ACTIVA POR VIRUS EPSTEIN BARR

Ramiro Sa Silva⁺⁻
Eira García⁺⁻
Emma González⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-04-06

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

La infección activa crónica por el virus Epstein Barr es pobremente diagnosticada y tiene alta morbimortalidad, se intenta realizar una revisión de lo reportado en la literatura del mismo.El Epstein Barr es un virus de doble cadena de DNA,pertenece a la familia Herpesviridae, contiene una nucleocápside icosahedra y una envoltura, se mantiene latente en células B y se replica en su núcleo. La infección activa crónica por este virus es definida por 3 criterios: síntomasparecidosa la mononucleosis infecciosa persistente o recurrente de más de 6 meses de duración; patrón inusual de anticuerpos contra el Epstein Barr: aumento de anticuerpos contra el antígeno de la cápside y anticuerpos contra el antígeno temprano y/o detección de incremento del genoma del virus en tejidos afectados; enfermedad crónica que no pueda explicarse por otra enfermedad al momento del diagnóstico.Regímenes de tratamiento no han sido establecidos hasta el momento.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic Factors for Chronic Active Epstein-Barr Virus. The Journal of Infectious Diseases. 2003;187:527–33.
Cho S, Kim HS, Park HC, Ahn MJ, Yiul LY, Park KC. A case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder. The Korean Journal of Internal Medicine. 2004;19:124-127.
Hurt C, Tammaro D. Diagnostic Evaluation of Mononucleosis-Like Illnesses. The American Journal of Medicine. 2007;120:911.e1-911.e8.
Cohen J. Epstein-Barr virus infection. NEJM. September 3, 2009;343(7):481-492.
Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, et al. Proposed Guidelines for Diagnosing Chronic Active Epstein-Barr Virus Infection. American Journal of Hematology. 2005;80:64–69.
Kimura H, Hoshino Y, Hara S, Sugaya N, Kawada J, Shibata Y, et al. Differences between T Cell–Type and Natural Killer Cell–Type Chronic Active Epstein-Barr Virus Infection. The Journal of Infectious Diseases. 2005;191:531–9.
Lu G, Xie Z, Zhao S, Ye L, Wu RH, Liu CY, et al. Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases. Chin Med J. 2009;122(3):262-266.
Dagdemir A, Tasdemir HA, Dilber C, Gok F, Kubar A. Increased Intracranial Pressure Due to Chronic Active Epstein-Barr Virus Infection. Pediatr Neurol. 2006;35:352-355.
Gottschalk S. Clinical and Virological Characteristics of Patients with Chronic Active Epstein-Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation: Insights and Questions. Clinical Infectious Diseases. 2008;46:1535–6.
Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, et al. Infection VEB-associated hemophagocytic lymphohistiocytosis and chronic active VEB Differential cellular targets of Epstein-Barr virus infection between acute. Blood. 2001;98:1882-1888.
Lee JS, Kang JH, Lee GK, Park HJ. Treatment of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis with HLH-94 Protocol. J Korean Med Sci. 2005;20:209-14.
Gotoh K, Ito Y, Shibata-Watanabe Y, Kawada J, Takahashi Y, Yagasaki H, et al. Clinical and Virological Characteristics of 15 Patients with Chronic Active Epstein-Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases. 2008;46:1525–34.
Cho EY, Kim KH, Kim WS, Yoo KH, Koo HH, Ko YH. The Spectrum of Epstein-Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups. J Korean Med Sci. 2008;23:185-92.
Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328.
Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293.
Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543.
Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004;6:1.
Auwaerter PG. Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control? Expert Rev Anti Infect Ther. 2006;4:1039.
Rea TD, Russo JE, Katon W, Ashley RL. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001;14:234.
Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120:911.
Obel N, Hoier-Madsen M, Kangro H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS. 1996;104:424.
Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280-286.
Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, et al. Differential cellular targets of Epstein-Barr virus infection between acute VEB-associated hemophagocytic lymphohistiocytosis and chronic active VEB infection. Blood. 2001;98:1882-1888.

Palabras clave

PDF

Resumen visto - 3 veces
PDF descargado - 2

Licencia

Content Top

[1] Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic Factors for Chronic Active Epstein-Barr Virus. The Journal of Infectious Diseases. 2003;187:527–33.

[2] Cho S, Kim HS, Park HC, Ahn MJ, Yiul LY, Park KC. A case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder. The Korean Journal of Internal Medicine. 2004;19:124-127.

[3] Hurt C, Tammaro D. Diagnostic Evaluation of Mononucleosis-Like Illnesses. The American Journal of Medicine. 2007;120:911.e1-911.e8.

[4] Cohen J. Epstein-Barr virus infection. NEJM. September 3, 2009;343(7):481-492.

[5] Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, et al. Proposed Guidelines for Diagnosing Chronic Active Epstein-Barr Virus Infection. American Journal of Hematology. 2005;80:64–69.

[6] Kimura H, Hoshino Y, Hara S, Sugaya N, Kawada J, Shibata Y, et al. Differences between T Cell–Type and Natural Killer Cell–Type Chronic Active Epstein-Barr Virus Infection. The Journal of Infectious Diseases. 2005;191:531–9.

[7] Lu G, Xie Z, Zhao S, Ye L, Wu RH, Liu CY, et al. Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases. Chin Med J. 2009;122(3):262-266.

[8] Dagdemir A, Tasdemir HA, Dilber C, Gok F, Kubar A. Increased Intracranial Pressure Due to Chronic Active Epstein-Barr Virus Infection. Pediatr Neurol. 2006;35:352-355.

[9] Gottschalk S. Clinical and Virological Characteristics of Patients with Chronic Active Epstein-Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation: Insights and Questions. Clinical Infectious Diseases. 2008;46:1535–6.

[10] Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, et al. Infection VEB-associated hemophagocytic lymphohistiocytosis and chronic active VEB Differential cellular targets of Epstein-Barr virus infection between acute. Blood. 2001;98:1882-1888.

[11] Lee JS, Kang JH, Lee GK, Park HJ. Treatment of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis with HLH-94 Protocol. J Korean Med Sci. 2005;20:209-14.

[12] Gotoh K, Ito Y, Shibata-Watanabe Y, Kawada J, Takahashi Y, Yagasaki H, et al. Clinical and Virological Characteristics of 15 Patients with Chronic Active Epstein-Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases. 2008;46:1525–34.

[13] Cho EY, Kim KH, Kim WS, Yoo KH, Koo HH, Ko YH. The Spectrum of Epstein-Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups. J Korean Med Sci. 2008;23:185-92.

[14] Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328.

[15] Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293.

[16] Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543.

[17] Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004;6:1.

[18] Auwaerter PG. Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control? Expert Rev Anti Infect Ther. 2006;4:1039.

[19] Rea TD, Russo JE, Katon W, Ashley RL. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001;14:234.

[20] Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120:911.

[21] Obel N, Hoier-Madsen M, Kangro H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS. 1996;104:424.

[22] Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280-286.

[23] Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, et al. Differential cellular targets of Epstein-Barr virus infection between acute VEB-associated hemophagocytic lymphohistiocytosis and chronic active VEB infection. Blood. 2001;98:1882-1888.

Imagen de portada

Resumen

Descargas

Citas

Palabras clave

Licencia